Corporate ActionMay 6, 2026, 09:12 AM
Pulse Biosciences Board Approves Affiliate Stock Purchases via ATM
AI Summary
Pulse Biosciences' Board of Directors approved resolutions on May 5, 2026, permitting affiliates to purchase common stock through an existing at-the-market (ATM) Equity Distribution Agreement with TD Securities (USA) LLC. This agreement allows the company to sell up to $59,976,196 in common stock. Separately, Co-Chairman Robert Duggan, who beneficially owns approximately 72% of the company's outstanding stock, and CEO Paul LaViolette have indicated a likelihood to purchase shares in the near term at market prices, though no binding commitments have been made.
Key Highlights
- Pulse Biosciences Board approved resolutions on May 5, 2026, for affiliates to purchase common stock via ATM.
- The Equity Distribution Agreement with TD Cowen allows sales of up to $59,976,196 in common stock.
- Co-Chairman Robert Duggan, beneficial owner of ~72% of outstanding stock, may purchase shares.
- CEO Paul LaViolette has also indicated a likelihood to purchase shares in the near term.
- Any purchases by these individuals would be at the prevailing market bid price or better.
- No formal binding commitments have been made by Mr. Duggan or Mr. LaViolette.